Please assess the completion status of the following clinical trial:

Trial Title: Rosuvastatin/Ezetimibe vs Rosuvastatin in Korean Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 19 to 70 years~2. Patient with type 2 diabetes who needs treatment for hypercholesterolemia~3. Written informed consent~Exclusion Criteria:~1. Administration of lipid lowering agents for more than one week within 4 weeks prior to screening visit~2. Uncontrollable diabetes with HbA1c ≥ 8.5%~3. Fasting LDL-C ≤ 70 mg/dL~4. Fasting triglyceride ≥ 400 mg/dL~5. Total cholesterol ≥ 300 mg/dL~6. History of muscular disease or rhabdomyolysis due to use of statin~7. Hypersensitive to rosuvastatin or ezetemibe~8. Contraindications stated in the SPC of rosuvastatin or rosuvastatin/ezetimibe including the following:~   ① Severe renal disease (estimated GFR(MDRD) \< 30mL/min/1.73m2)~   ② ALT, AST \> 3x ULN or history of active liver disease~   ③ CPK \> 3x ULN~9. Administration of other investigational products within 30 days prior to screening visit~10. Other than the above who is deemed to be ineligible to participate in the trial by investigator

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Rosuvamibe® Tab (Type: EXPERIMENTAL): Rosuvamibe® Tab (rosuvastatin 5mg/ezetimibe 10mg) qd for 8 weeks
- Monorova® Tab (Type: ACTIVE_COMPARATOR): Monorova® Tab (rosuvastatin 10mg) qd for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).